Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28803469 | 0.89 | EPHX2 (0.39) | EPHX2SPHK2 | |
| SCHEMBL5986523 | 0.89 | EPHX2 (0.39) | EPHX2SPHK2 | |
| SCHEMBL8908940 | 0.88 | EPHX2 (0.39) | EPHX2 | |
| SCHEMBL8908943 | 0.88 | EPHX2 (0.39) | EPHX2 | |
| SCHEMBL600824 | 0.87 | GNAI3 (0.31) | — | |
| SCHEMBL17592150 | 0.87 | GNAI3 (0.31) | — | |
| SCHEMBL600825 | 0.87 | GNAI3 (0.31) | — | |
| SCHEMBL20337456 | 0.84 | OPRM1 (0.33) | EPHX2 | |
| SCHEMBL20807864 | 0.81 | NPC1 (0.42) | EPHX2SPHK2 | |
| SCHEMBL27905310 | 0.81 | NPC1 (0.38) | EPHX2SPHK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11351173-B2 | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2022-06-07 | — | — | US | disclosed |
| US-20210177853-A1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2021-06-17 | — | — | US | disclosed |
| US-10751341-B2 | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders | LYSOSOMAL THERAPEUTICS INC. (US) | 2020-08-25 | — | — | US | disclosed |
| EP-3215509-B1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC (US) | 2020-02-26 | — | — | EP | disclosed |
| US-20200030331-A1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2020-01-30 | — | — | US | disclosed |
| US-20180185368-A1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. (US) | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11351173-B2 | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders | TYMP, PARK7, PNP | EPHX2 2976/4885SPHK2 794/4885 |
| US-20210177853-A1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | TYMP, PARK7, PNP | EPHX2 2976/4885SPHK2 794/4885 |
| US-10751341-B2 | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders | TYMP, PARK7, PNP | EPHX2 2976/4885SPHK2 794/4885 |
| US-20200030331-A1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | TYMP, PARK7, PNP | EPHX2 2976/4885SPHK2 794/4885 |
| US-20180185368-A1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | TYMP, PARK7, PNP | EPHX2 2976/4885SPHK2 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.